Foundayo (Orforglipron) Cost: Price, Savings & Coverage
Foundayo is the first oral GLP-1 pill approved for weight loss, and its main selling point against the injectables is price. The list price sits near $499 a month, but most people will pay one of several lower numbers depending on insurance, Medicare status, or whether they buy cash through LillyDirect. Here is the full pricing picture, including the Medicare change taking effect July 1, 2026.
Foundayo Cost at a Glance
Four prices matter, and which one applies to you depends entirely on coverage. The table sorts them from list price down to the lowest available out-of-pocket cost.
| Pathway | Approx. Monthly Cost | Who It Applies To |
|---|---|---|
| List price (WAC) | ~$499 | Reference price before any discount or coverage |
| LillyDirect self-pay | From ~$149 (lowest dose) | Cash-pay patients buying direct |
| Medicare Part D | As low as $50 (from Jul 1, 2026) | Eligible Part D patients |
| Commercial savings card | As low as $25 | Eligible commercially insured patients |
For the full drug profile rather than just pricing, see our Foundayo guide and the orforglipron overview.
List Price vs What You Actually Pay
The ~$499 list price is the reference number, not the typical out-of-pocket cost. Lilly set it well below the roughly $1,300 to $1,500 list price of injectable Wegovy and Zepbound. From there, savings programs, Medicare pricing, and cash-pay tiers each knock the number down further. The practical takeaway: almost no one with a way to access a discount pays the full $499.
Commercial Insurance and the $25 Savings Card
If you have commercial (employer or marketplace) insurance that covers GLP-1s for obesity, the manufacturer savings card can bring your cost down to about $25 per month. It works the same way as Lilly's Zepbound card. Two conditions usually apply: your plan has to cover Foundayo on its formulary, and you cannot be on a government plan like Medicare or Medicaid. Many plans also require prior authorization documenting BMI and weight-related conditions.
If your commercial plan excludes weight-loss drugs entirely, the card does not rescue you, because there is no covered benefit to discount against. In that case the cash-pay route is usually cheaper than fighting the formulary.
Self-Pay Through LillyDirect
Lilly sells Foundayo directly to cash-pay patients through LillyDirect, with self-pay pricing that starts around $149 per month for the lowest dose and increases at higher doses. This is the path for people without GLP-1 coverage, and it undercuts the cash cost of every injectable GLP-1. Compared with semaglutide without insurance or tirzepatide without insurance, the oral pill is the lower-cost branded option.
Medicare and Medicaid: The July 1 Change
Medicare historically does not cover GLP-1 drugs prescribed for weight loss alone, which has left older adults paying cash. Lilly has said eligible Medicare Part D patients may pay as little as $50 per month for Foundayo beginning July 1, 2026. That is a meaningful shift, but eligibility and plan-specific terms decide whether it reaches you, so confirm with your Part D plan rather than assuming. State Medicaid coverage varies; Foundayo's lower price may make some state programs more willing to add it than they were for the pricier injectables.
How Foundayo Pricing Compares to Wegovy and Zepbound
On cash price, Foundayo is the clear budget option. On insured price with a savings card, the three converge near $25 a month for eligible patients. The real differences show up for cash-pay and Medicare patients, where Foundayo's lower list and self-pay prices matter most.
| Drug | Form | Approx. List Price/Month |
|---|---|---|
| Foundayo (orforglipron) | Oral pill | ~$499 |
| Wegovy (semaglutide) | Injection | ~$1,350 |
| Zepbound (tirzepatide) | Injection | ~$1,060–$1,300 |
Price is not the only variable. Injectable tirzepatide still produces larger average weight loss than orforglipron in trials, so the cheaper pill is not automatically the better choice. See Foundayo vs Zepbound, Foundayo vs Wegovy, and which GLP-1 is best for weight loss.
Why an Oral GLP-1 Can Be Priced Lower
Orforglipron is a small-molecule drug, not a peptide. That means it can be made by standard chemical synthesis and pressed into a tablet, avoiding the costlier peptide manufacturing and pen-injector assembly behind semaglutide and tirzepatide. Cheaper production scales better, and Lilly used that headroom to price aggressively and broaden access. It is the same reason the oral format is expected to expand the GLP-1 market rather than just split the existing one.
How to Get Foundayo for the Lowest Cost
The cheapest route depends on your coverage. Commercially insured with GLP-1 benefits: use the $25 savings card. Medicare Part D: check whether the $50 price applies to your plan after July 1, 2026. No GLP-1 coverage: use LillyDirect self-pay from around $149. Before committing, confirm the prescribed dose, since self-pay cost rises at higher doses, and review side effect expectations in our orforglipron side effects guide.
Related Guides
Frequently Asked Questions About Foundayo Cost
Foundayo (orforglipron) has a list price of roughly $499 per month. What you actually pay depends on coverage: eligible commercially insured patients can pay as little as $25 per month with the manufacturer savings card, LillyDirect self-pay starts around $149 per month for the lowest dose, and eligible Medicare Part D patients can pay as little as $50 per month beginning July 1, 2026.
Yes, on list price. Foundayo lists near $499 per month versus roughly $1,300 to $1,500 for injectable Wegovy and Zepbound before discounts. The gap narrows once savings cards are applied, since all three offer a $25 commercial-insurance program, but for cash-pay patients Foundayo is meaningfully less expensive.
Coverage is mixed and still developing. Commercial plans that cover GLP-1s for obesity are adding Foundayo, and its lower price makes it easier for cost-sensitive plans to include. Plans that exclude weight-loss drugs entirely will still exclude Foundayo. Check your formulary, and expect prior authorization in many cases, as with other GLP-1s.
Eligible patients with commercial (non-government) insurance can use the manufacturer savings card to lower their out-of-pocket cost to about $25 per month. It mirrors Lilly's existing Zepbound program. People on Medicare, Medicaid, or other federal plans are not eligible for the commercial card, which is why the separate Medicare price matters.
Beginning July 1, 2026, eligible Medicare Part D patients may pay as little as $50 per month for Foundayo, according to Lilly. This is notable because Medicare generally does not cover GLP-1 drugs prescribed for weight loss alone, so the pathway and eligibility details matter. Confirm your specific Part D plan terms before assuming the $50 price applies.
Yes. Lilly sells Foundayo direct to cash-pay patients through LillyDirect, with self-pay pricing that starts around $149 per month for the lowest dose and rises at higher doses. That is well below the cash cost of injectable GLP-1s, which is part of why the oral pill is positioned as the budget-friendlier option.
Orforglipron is a small molecule, not a peptide. It can be manufactured by conventional chemical synthesis and packaged as a tablet, which is cheaper to produce and scale than the peptide synthesis and pen-injector assembly behind semaglutide and tirzepatide. Lilly passed part of that lower cost into the price, partly to compete and partly to widen access.
Possibly. Oral manufacturing scales well, and competition from other oral GLP-1s in development could push prices down. But it is brand-protected with no generic, so large drops are unlikely in the near term. The most reliable savings today come from the commercial card, the Medicare price, or LillyDirect self-pay rather than waiting for a list-price cut.